[go: up one dir, main page]

DE69928523D1 - Verotoxin b untereinheit zur immunisierunug - Google Patents

Verotoxin b untereinheit zur immunisierunug

Info

Publication number
DE69928523D1
DE69928523D1 DE69928523T DE69928523T DE69928523D1 DE 69928523 D1 DE69928523 D1 DE 69928523D1 DE 69928523 T DE69928523 T DE 69928523T DE 69928523 T DE69928523 T DE 69928523T DE 69928523 D1 DE69928523 D1 DE 69928523D1
Authority
DE
Germany
Prior art keywords
verotoxin
immunization
sub
unit
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928523T
Other languages
English (en)
Other versions
DE69928523T2 (de
Inventor
Allan M Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Curie
Original Assignee
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie filed Critical Institut Curie
Application granted granted Critical
Publication of DE69928523D1 publication Critical patent/DE69928523D1/de
Publication of DE69928523T2 publication Critical patent/DE69928523T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Silicon Polymers (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69928523T 1998-05-15 1999-05-14 Verotoxin b untereinheit zur immunisierunug Expired - Lifetime DE69928523T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8569398P 1998-05-15 1998-05-15
US85693P 1998-05-15
PCT/US1999/010679 WO1999059627A2 (en) 1998-05-15 1999-05-14 Verotoxin b subunit for immunization

Publications (2)

Publication Number Publication Date
DE69928523D1 true DE69928523D1 (de) 2005-12-29
DE69928523T2 DE69928523T2 (de) 2006-08-10

Family

ID=22193333

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928523T Expired - Lifetime DE69928523T2 (de) 1998-05-15 1999-05-14 Verotoxin b untereinheit zur immunisierunug

Country Status (9)

Country Link
US (2) US20020081307A1 (de)
EP (1) EP1078007B1 (de)
JP (1) JP4820000B2 (de)
AT (1) ATE310750T1 (de)
AU (1) AU3991899A (de)
CA (1) CA2333921C (de)
DE (1) DE69928523T2 (de)
ES (1) ES2255269T3 (de)
WO (1) WO1999059627A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
AU2003303374A1 (en) * 2002-12-20 2004-07-22 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US7182661B2 (en) * 2005-02-24 2007-02-27 David Bryan Sams Detachable surfboard fin system
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
EP2072060A1 (de) 2007-12-18 2009-06-24 Institut Curie Verfahren und Zusammensetzungen zur Herstellung und Verwendung von Toxinkonjugaten

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2547731A1 (fr) 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US5198344A (en) 1986-07-15 1993-03-30 Massachusetts Institute Of Technology DNA sequence that encodes the multidrug resistance gene
US5338839A (en) 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
AU657087B2 (en) 1989-12-22 1995-03-02 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
CA2077277A1 (en) * 1991-09-09 1993-03-10 John J. Donnelly Cellular immunity vaccines from bacterial toxin-antigen conjugates
DE4219696A1 (de) * 1992-02-17 1993-08-19 Biotechnolog Forschung Gmbh Hybrid-dna, plasmide, oligohybridpeptid und impfstoff
WO1993017115A2 (en) 1992-02-18 1993-09-02 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
US5350890A (en) 1992-10-01 1994-09-27 Gould Instrument Systems, Inc. Contact switch device
JPH08506963A (ja) * 1993-02-22 1996-07-30 ザ ジェネラル ホスピタル コーポレーション 生ワクチン菌株における異種抗原
US7229755B1 (en) 1993-11-17 2007-06-12 Dana Farber Cancer Institute, Inc. Method for detection of alterations in the DNA mismatch repair pathway
WO1996016178A1 (en) * 1994-11-17 1996-05-30 Maxim Pharmaceuticals, Inc. Immunogens for stimulating mucosal immunity
EP0739984A1 (de) 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalente Polypeptiden die mindestens zwei Bereichen enthalten
WO1997013410A1 (en) 1995-10-13 1997-04-17 Boston Medical Center Corporation Hybrid molecules containing amidated polypeptide binding ligands
JP2001500730A (ja) * 1996-09-10 2001-01-23 ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6482586B1 (en) 1996-11-22 2002-11-19 Hospital For Sick Children Research And Development Limited Partnership Hybrid compositions for intracellular targeting
FR2766193B1 (fr) * 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique

Also Published As

Publication number Publication date
WO1999059627A3 (en) 2000-01-20
CA2333921C (en) 2014-04-22
ES2255269T3 (es) 2006-06-16
DE69928523T2 (de) 2006-08-10
AU3991899A (en) 1999-12-06
US20020081307A1 (en) 2002-06-27
US20040013681A1 (en) 2004-01-22
US8367071B2 (en) 2013-02-05
ATE310750T1 (de) 2005-12-15
WO1999059627A2 (en) 1999-11-25
JP2002515456A (ja) 2002-05-28
CA2333921A1 (en) 1999-11-25
EP1078007A2 (de) 2001-02-28
JP4820000B2 (ja) 2011-11-24
EP1078007B1 (de) 2005-11-23

Similar Documents

Publication Publication Date Title
NO983999D0 (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
HRP20010877B1 (hr) Pripravci za prevenciju i liječenje amiloidogenskih bolesti
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
AU7814498A (en) Multivalent (in ovo) avian vaccine
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
DK0944396T3 (da) Præparater og fremgangsmåder til forøgelse af tarmfunktion
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DK0527879T3 (da) Synergistiske terapeutiske præparater og fremgangsmåder.
TR199802423T2 (xx) Konsantre antikor terkibi.
CA2310888A1 (en) Monoclonal human natural antibodies
ATE127345T1 (de) Stressproteine und verwendungen dafür.
BR9913446A (pt) Produtos de aglicona e métodos de uso
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
EA199900342A1 (ru) Способ создания активного иммунитета вакцинным конъюгатом
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
DK1082131T3 (da) Immunoregulator
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
EP0836480A4 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität ausweisen und methoden für ihre herstellung und die verwendung derselben

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER VERTRETER IST ZU BERICHTIGEN IN: MUELLER SCHUPFNER, 21244 BUCHHOLZ

8364 No opposition during term of opposition